Top

International Journal of Colorectal Disease

Published in:

01-08-2008 | Original Article

Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients

Authors: Katja Ott, Florian Lordick, Karen Becker, Kurt Ulm, JörgRüdiger Siewert, Heinz Höfler, Gisela Keller

Published in: International Journal of Colorectal Disease | Issue 8/2008

Abstract

Objective

Neoadjuvant chemotherapy in gastric cancer is now standard in the Western world; however, only 30–40% of the patients respond to induction therapy. Pretherapeutic predictors of response and prognosis would be of utmost interest to individualize treatment. Glutathione-S-transferase enzymes detoxify therapeutic drugs such as platin derivates and may influence outcome of the treated patients. Therefore, glutathione-S-transferase (GST) polymorphisms were assessed as predictive markers in cisplatinum-based neoadjuvant-treated gastric cancer.

Materials and methods

DNA was isolated from 139 patients with locally advanced gastric cancer (cT3/4 anyN cM0) before chemotherapy. Multiplex polymerase chain reaction was used for GSTT1 and GSTM1 genes, and allelic discrimination assay with the TaqMan system for the GSTP1 gene.

Results

One hundred ten patients could be analyzed for GSTT1 (T-:23; T + 87), 112 for GSTM1 (M-:52; M +:60) and 132 for GSTP1 (Ile/Ile: 55; Ile/Val: 59; Val/Val: 18). There was no significant correlation between any of the GSTT1, GSTM1, or GSTP1 genotypes and patients’ characteristics or histopathological data; only the GSTM1+ genotype was associated with the non-intestinal subtype of the Lauren classification (p = 0.045). GSTT1, GSTM1, and GSTP1 genotypes were not correlated with response to chemotherapy (p = 0.57, p = 0.38, p = 0.33). In R0 resected patients, we found an improved survival for patients with the GSTM1-present genotype compared to patients with the GSTM1-null genotype (p = 0.017). Moreover, the GSTM1-present genotype showed a significantly better tumor-related (p = 0.017) and disease-free survival (p = 0.029).

Conclusion

None of the common GST polymorphisms predicts response in our study, but the GSTM1+ genotype was associated with a better prognosis in completely resected patients. Further investigations on chemotherapy-associated gene polymorphisms are warranted.

Cunningham D, Allum WH, Stenning SP, Thompson JN et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef

Boige V, Pignon J, Saint-Aubert B, Lasser P, Conroy T, Bouche O, Segol P, Bedenne L, Rougier P, Ychou M (2007) Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol (Supplement) 25:18S (Abstract)

Ott K, Sendler A, Becker K, Dittler HJ et al (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6:159–167PubMedCrossRef

Lordick F, Stein HJ, Peschel C, Siewert JR (2004) Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 91:540–551PubMedCrossRef

Napieralski R, Ott K, Kremer M, Becker K et al (2007) Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 13:5095–5102PubMedCrossRef

Ott K, Vogelsang H, Marton N, Becker K et al (2006) The thymidylate synthase tandem repeat promoter polymorphism: a predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119:2885–2894PubMedCrossRef

Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 85:7293–7297PubMedCrossRef

Srivastava SK, Singhal SS, Hu X, Awasthi YC et al (1999) Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 366:89–94PubMedCrossRef

Hayes JD, Pulford DJ (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30:445–600PubMedCrossRef

10.

Dirven HA, Dictus EL, Broeders NL, van Ommen B et al (1995) The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res 55:1701–1706PubMed

11.

Weijl NI, Cleton FJ, Osanto S (1997) Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209–240PubMedCrossRef

12.

La Torre F, Silipigni AM, Orlando A, La T I et al (1997) [Role of free radicals, telomeres, and telomerases in aging and cancerogenesis]. Minerva Med 88:205–214PubMed

13.

Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N et al (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63:8097–8102PubMed

14.

Goekkurt E, Hoehn S, Wolschke C, Wittmer C et al (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)—novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286PubMedCrossRef

15.

Okuyama T, Maehara Y, Endo K, Baba H et al (1994) Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74:1230–1236PubMedCrossRef

16.

Davies SM, Robison LL, Buckley JD, Tjoa T et al (2001) Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 19:1279–1287PubMed

17.

DeMichele A, Aplenc R, Botbyl J, Colligan T et al (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23:5552–5559PubMedCrossRef

18.

Casson AG, Zheng Z, Chiasson D, MacDonald K et al (2003) Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 27:139–146PubMedCrossRef

19.

Schuhmacher CP, Fink U, Becker K, Busch R et al (2001) Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 91:918–927PubMedCrossRef

20.

Ott K, Fink U, Becker K, Stahl A et al (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604–4610PubMedCrossRef

21.

Menzel C, Dobert N, Rieker O, Kneist W et al (2003) [18F-Deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading]. Nuklearmedizin 42:90–93PubMed

22.

Ott K, Dittler HJ, Helmberger H (2000) Preoperative chemotherapy of high dose 5-FU (HDFU) + folinic acid (HDFA) + biweekly Cisplatin without (group A) or with Paclitaxel (group B) in patients with locally advanced adenocarcinomas of the esophagus. Proc Am Soc Clin Oncol 19:287A (Abstract)

23.

Becker K, Mueller JD, Schulmacher C, Ott K et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530PubMedCrossRef

24.

Ott K, Weber WA, Lordick F, Becker K et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692–4698PubMedCrossRef

25.

Ott K, Vogelsang H, Mueller J, Becker K et al (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307–2315PubMed

26.

Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Mostafa HM et al (1998) GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer. Cancer Detect Prev 22:129–138PubMedCrossRef

27.

Ambrosone CB, Sweeney C, Coles BF, Thompson PA et al (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130–7135PubMed

28.

Sweeney C, McClure GY, Fares MY, Stone A et al (2000) Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 60:5621–5624PubMed

29.

Sweeney C, Nazar-Stewart V, Stapleton PL, Eaton DL et al (2003) Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12:527–533PubMed

30.

Choi SC, Yun KJ, Kim TH, Kim HJ et al (2003) Prognostic potential of glutathione S-transferase M1 and T1 null genotypes for gastric cancer progression. Cancer Lett 195:169–175PubMed

31.

Stoehlmacher J, Park DJ, Zhang W, Groshen S et al (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 19(94):936–942

32.

Lee JM, Wu MT, Lee YC, Yang SY et al (2005) Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11:4749–4753PubMedCrossRef

33.

Howells RE, Dhar KK, Hoban PR, Jones PW et al (2004) Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. Int J Gynecol Cancer 14:242–250PubMedCrossRef

34.

Roder JD, Bottcher K, Siewert JR, Busch R et al (1993) Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72:2089–2097PubMedCrossRef

35.

Yang G, Shu XO, Ruan ZX, Cai QY et al (2005) Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer 103:52–58PubMedCrossRef

Title: Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients
Authors: Katja Ott
Florian Lordick
Karen Becker
Kurt Ulm
JörgRüdiger Siewert
Heinz Höfler
Gisela Keller
Publication date: 01-08-2008
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 8/2008
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-008-0490-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients

Abstract

Objective

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2008

Proximal colon cancer in patients aged 51–60 years of age should be tested for microsatellites instability. A comment on the Revised Bethesda Guidelines

Rapidly progressive metastatic multicentric epithelioid angiosarcoma of the small bowel: a case report and a review of literature

Evaluation of vector manometry for characterization of functional outcome after restorative proctocolectomy

Colonic endometriosis with malignant transformation mimicking a diverticular abscess

Clinical outcomes and patency of self-expanding metal stents in patients with malignant colorectal obstruction: a prospective single center study

Detailed evaluation of functional recovery following laparoscopic or open surgery for colorectal cancer within an enhanced recovery programme